Navigation Links
Sosei Announces Filing of NDA for SOH-075 (NorLevo(R)) in Japan
Date:9/30/2009

TOKYO, September 30 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced the submission of the New Drug Application (NDA) for the emergency contraceptive pill SOH-075 (NorLevo(R)) to Ministry of Health, Labour and Welfare (MHLW) by Sosei Co. Ltd., its wholly owned Japanese subsidiary.

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse.

Sosei has acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA is supported by the data from Phase III study that was successfully completed in October 2008.

Editor's Notes:

About Sosei

Sosei Group is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit http://www.sosei.com

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
2. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
3. Sosei Announces Outcome of Strategy Review
4. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
5. EPA announces research strategy to study nanomaterials
6. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
7. MAQUET Cardiovascular Announces Leading Robotic Heart Surgeon Performs First Beating Heart Fully Endoscopic Bypass Surgery Using Miniaturized Cardiopulmonary Bypass System
8. Axial Biotech Announces Commercial Availability of SCOLISCORE(TM) AIS Prognostic Test
9. Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock
10. Spherix Incorporated Announces Annual Shareholders Meeting Date
11. Compendia Bioscience Announces the Release of Oncomine 4 Research Edition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 29, 2017 , ... ACEA Biosciences, a privately owned biotechnology ... award to noteworthy scientists who will be presenting research using ACEA Biosciences’ technology ... awards are being given to two postdoctoral fellows studying pathogen capture by neutrophils, ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - The University ... partners Nordion, a business of Sterigenics International, and General ... has been submitted to the U.S. Nuclear Regulatory Commission ... U.S. production of molybdenum-99 (Mo-99). Once operational, production from ... of U.S. demand for Mo-99, which currently must be ...
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions announced ... processes and enhance training plan management for consistent implementation of standards and regulatory ... the SHL Group to help improve and streamline their training and employee development ...
(Date:3/28/2017)... ... March 28, 2017 , ... Triumph ... Modular Building Institute (MBI), an international modular trade organization, were awarded First Place, ... for the Pagliuca Life Lab at Harvard University. The awards were presented at ...
Breaking Biology Technology:
(Date:2/28/2017)... Februar 2017  EyeLock LLC, ein marktführendes Unternehmen im ... biometrische Lösung zur Iris-Erkennung auf der neuesten ... auf dem Mobile World Congress 2017 (27. ... Halle 3, Stand 3E10, vorstellen. ... Haven™ – eine Kombination aus Hardware, Software ...
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
Breaking Biology News(10 mins):